Skip to main content
Premium Trial:

Request an Annual Quote

From AFCS, Painstaking Pathways

Premium

I enjoyed reading Nat Goodman’s article “Can’t Get There From Here” in the latest issue of GT (June ’03). He did well in presenting the problems of navigating not only through signaling pathways, but also through the varied websites that are attempting to represent them.

I want to point out that the AfCS-Nature Signaling Gateway does indeed contain a few pathway maps within its Molecule Page section (http://www.signaling-gateway.org/molecule/maps). It is only a modest set of pathways at the moment, but we plan on expanding the list as well as developing more dynamic ways of using them to view experimental data and linking them to the Molecule Pages.

We are also exploring new ways of representing complex pathways to make navigation easier and more meaningful (check out a recent paper we posted on the subject: http://www.signaling-gateway.org/reports/v1/DA0009.pdf). We hope to create a valuable resource for signal transduction scientists, so keep checking our site for new developments.

 

Gilberto R. Sambrano, PhD
System Committees Coordinator
Alliance for Cellular Signaling

Send us your thoughts

Don’t be shy. Tell us what you think. Send e-mail to [email protected]
or mail to: Editor, Genome Technology, PO Box 998, New York, NY 10272-0998

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.